YHLO Offers Series of SARS-CoV-2 Antigen Test Products to Meet Demand for Global COVID-19 Mass Screening

Shenzhen YHLO Biotech Co., Ltd. (Shenzhen, China) is offering a series of SARS-CoV-2 antigen test products to meet the growing demand for global COVID-19 mass screening.

As the COVID-19 global pandemic continues to increase in severity, the demand for mass screening continues to grow, making SARS-CoV-2 antigen tests an ideal option. Despite their relatively limited sensitivity, the significant specificity of COVID-19 antigen tests reported (99.5%) enables quick decisions regarding patient management. The reliable test results provided by SARS-CoV-2 antigen tests allow for timely identification of COVID-19 positive individuals. Unlike PCR assays, antigen tests offer several point-of-care advantages that make large-scale screening possible with minimal clinical laboratory and technician support.


In addition to diagnosis, COVID-19 antigen tests also allow for monitoring the clinical condition of diagnosed patients. Antigen tests can distinguish between the early and late phases of COVID-19, as the level of viral antigens has an inverse relationship with the progress of the disease. The information provided by antigen tests about a patient’s current infectious status is helpful in making clinical interpretations for the management of COVID-19 infected inpatients (differentiated isolation, ward transfer, discharge, etc.).

To assist in the efforts to combat the global pandemic, YHLO has launched iFlash-2019-nCoV Antigen Assay, GLINE-2019-nCoV Antigen Assay and UNICELL-2019-nCoV Ag Test, all of which are officially CE marked for international sales. These antigen assays are superior due to several features. For instance, YHLO’s iFlash-2019-nCoV Antigen Assay offers reliable results due to its high sensitivity and specificity, and has a high throughput of up to 300 tests per hour. In addition, its automated workflow reduces manual operation and prevents cross-infection for operators.

Similarly, YHLO’s GLINE-2019-nCoV Antigen Assay is completely electronic equipment-free, requires minimal operations, supports nasal/nasopharyngeal swab and delivers results within 15 minutes. YHLO’s affordable UNICELL-2019-nCoV Ag Test requires minimal laboratory operations and delivers time-saving results within 15 minutes in addition to offering the advantages of compact size for easy transportation & storage and traceable results for up to 5,000 result memories.